Pharmaceutical companies request patents for cancer drugs and veterinary antiparasitics in Nicaragua

The Intellectual Property Registry of Nicaragua published in La Gaceta, Official Gazette No. 174 on Thursday, September 24, 2026, three invention patent applications filed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Blossomhill Therapeutics, Inc., and Agrovet Market S.A. The notices grant a period of 15 business days, counted from their delivery, for interested parties to submit observations to the General Directorate of the Intellectual Property Registry. The applications were registered under files 2026-000031 I, 2026-000038 I, and 2026-000045 I.

The three notices are issued under Article 33 of Law No. 354, “Law on Invention Patents, Utility Models, and Industrial Designs,” which empowers third parties to oppose an application before its granting. The files were submitted between May and June 2026 and claim foreign priority in China, the United States, and Peru.

The notices for Agrovet Market S.A. and Blossomhill Therapeutics, Inc. were issued in Managua on August 13, 2026; that of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., on August 21, 2026. All appear in the Factory, Trade, and Service Marks section of the Intellectual Property Registry, which in this issue covers page 9331 and following.

Antibody-drug conjugates targeting EGFR/C-MET

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., domiciled in Chengdu, Sichuan (China), applies for patent 2026-000031 I, filed on May 14, 2026, for “Antibody-drug conjugates targeting EGFR/C-MET and methods of preparation and uses thereof.” Representation is exercised by Darliss Marcela Gordon Arana.

The invention describes antibody-drug conjugates (ADC) with a bispecific antibody—one arm targeting EGFR and another targeting c-MET—linked to a cytotoxic drug, useful for preventing, treating, or acting as an adjuvant in diseases related to c-MET and/or EGFR. It claims priority in China (7/11/2024, 202411591580.6; 15/11/2023, 202311531642.X; and 24/11/2023, 202311596146.2).

Inventors: Hongmei Song, Yuzhi Pu, Yong Zheng, Xiangyang Tan, Junyou Ge, Yuehua Zhou, Qiang Tian, Miao Tan, Hu Long, Ruibin Hu, Dongmei Lei, Xiaoxi Yuan, and Yanshu Di.

Polymorphs of the indazole macrocycle

Blossomhill Therapeutics, Inc., of San Diego, California (United States), applies for patent 2026-000038 I, filed on June 5, 2026, for “Polymorphs of the indazole macrocycle.” Marina Betania Bojorque Rivera acts as the proxy.

The abstract indicates that the polymorphs of (17E)-16-ethyl-8,12,14-trimethyl-2,11,12,14-tetrahydro-8H-3,5-etenotripyrazole are useful in the treatment of diseases such as cancer in mammals, including humans. Priority claimed: United States 7/12/2023 (63/607,349) and 11/26/2024 (63/725,441).

Inventors: Evan W. Rogers, Chialu K. Chang, Z. Jesse Shao, Eugene Yuanjin Rui, Jingrong Jean Cui, Antonio Garrido-Montalban, and Wanlong Jiang.

Isoxazoline bioadhesive gel for veterinary use

Agrovet Market S.A., domiciled in Lima (Peru), applies for patent 2026-000045 I, filed on June 19, 2026, for an “Oral composition in the form of an isoxazoline-based bioadhesive gel.” The attorney is Marina Betania Bojorque Rivera.

The composition is a long-acting bioadhesive endoparasiticide gel, with high adhesion to the oral mucosa and high palatability, which allows the administration of isoxazolines at concentrations of up to 20.0% weight/volume, overcoming the organoleptic and physicochemical limitations of tablet formulations. It claims priority in Peru (12/21/2023, 003443-2023/DIN).

Inventors: Jorge Umberto Calderón Ojeda, Mauricio Yvan Porras Nicho, Karen Melissa Delgado Crispín, and Erick Alfredo Molleapaza Aguilar.

Period for observations and errata

• Notice validity: 15 business days from its delivery.
• Authority before which observations are presented: General Directorate of Intellectual Property Registry, Managua.
• Open files: 2026-000031 I, 2026-000038 I, and 2026-000045 I.
• Publication records: Reg. 2026-M3087, Reg. 2026-M3133, and Reg. 2026-M3131.

The same issue includes an Errata correcting the abstract of application 2026-000018 I, published in Gazette No. 148-2026 on August 12, 2026, where “calda” was recorded instead of “caída”.

The three applications confirm that Nicaragua remains a registration hub for pharmaceutical and veterinary developments of Chinese, American, and Peruvian origin. For industry readers, the practical detail is the clock: any prior rights holder or competitor has only 15 business days from the delivery of the notice to oppose; if granted, these patents would provide territorial protection in Nicaragua for bispecific oncological therapies and antiparasitic formulations for veterinary use.

Source: La Gaceta, Official Diary No. 174, Thursday, September 24, 2026, Intellectual Property Registry — Trademarks, Trade and Services, pp. 9331-9345 (official reference: Reg. 2026-M3087, Reg. 2026-M3133, and Reg. 2026-M3131).